Andrew N. Schiff's Insider Trades & SAST Disclosures
Andrew N. Schiff's most recent trade in Monte Rosa Therapeutics Inc was a trade of 22,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew N. Schiff.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 4,793 | 4,793 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 9,167 (0%) | 0% | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 4,507 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 10 Nov 2022 | 41,160 | 435,826 (1%) | 0% | 17.1 | 702,177 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 10 Nov 2022 | 11,395 | 476,986 (1%) | 0% | 17.0 | 193,995 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.08 per share. | 10 Nov 2022 | 1,371 | 434,455 (1%) | 0% | 17.1 | 23,417 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 24 Oct 2022 | 14,616 | 514,939 (1%) | 0% | 17.0 | 248,586 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 24 Oct 2022 | 14,540 | 488,381 (1%) | 0% | 17.0 | 247,253 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 24 Oct 2022 | 12,018 | 502,921 (1%) | 0% | 17.0 | 204,516 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 16.89 per share. | 17 Oct 2022 | 32,093 | 529,555 (1%) | 0% | 16.9 | 542,022 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 17 Oct 2022 | 19,944 | 561,648 (1%) | 0% | 16.0 | 320,087 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 16.16 per share. | 07 Oct 2022 | 7,324 | 581,592 (1%) | 0% | 16.2 | 118,349 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 16.54 per share. | 04 Oct 2022 | 37,839 | 588,916 (1%) | 0% | 16.5 | 625,744 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 04 Oct 2022 | 7,700 | 626,755 (1%) | 0% | 16.0 | 123,259 | Common Stock |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Sale of securities on an exchange or to another person at price $ 15.14 per share. | 17 Jun 2022 | 19,565 | 0 (0%) | 0% | 15.1 | 296,269 | Common Stock |
| Monte Rosa Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 19,565 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Monte Rosa Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 47,132 | 47,132 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 16,500 | 16,500 | - | - | Option Grant (right to buy) | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 7,333 | 16,209 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew N. Schiff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 7,333 | 0 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges